RGEN - Repligen Corporation
100.71 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 99.90 |
| Open | 100.74 |
| Bid | 100.70 x 800 |
| Ask | 100.73 x 900 |
| Day's Range | 99.66 - 100.90 |
| 52 Week Range | 52.87 - 101.00 |
| Volume | 252,291 |
| Avg. Volume | 400,507 |
| Market Cap | 5.243B |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | 201.82 |
| EPS (TTM) | 0.50 |
| Earnings Date | Feb 18, 2020 - Feb 23, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 107.78 |
- Zacks
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
- Simply Wall St.
Investors Who Bought Repligen (NASDAQ:RGEN) Shares Five Years Ago Are Now Up 289%
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
- Investor's Business Daily
Stocks To Watch: Life Sciences Leader Repligen Tests New Buy With 84% Growth
Boosted by average EPS growth of 84% over the last three quarters, life sciences leader and biologic drugmaker Repligen is now testing a new buy point.
- Investor's Business Daily
Breakout Stocks & Technical Analysis
Get alerts to potential breakout stocks, along with technical analysis of the stock charts to see the best time to buy and what telltale signs to look for.
- GlobeNewswire
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
Repligen Corporation (RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38th annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis in San Francisco. Tony J. Hunt, Repligen’s president and chief executive officer, is scheduled to present a company overview on Wednesday, January 15, 2020 at 11:30 a.m. PT. A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website at www.repligen.com.
- Simply Wall St.
A Look At The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
Today we will run through one way of estimating the intrinsic value of Repligen Corporation (NASDAQ:RGEN) by taking...
- Zacks
Has Repligen (RGEN) Outpaced Other Medical Stocks This Year?
Is (RGEN) Outperforming Other Medical Stocks This Year?
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Repligen Corporation (RGEN)
How do we determine whether Repligen Corporation (NASDAQ:RGEN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- Zacks
3 Reasons Growth Investors Will Love Repligen (RGEN)
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Zacks
Here's Why Repligen (RGEN) is a Great Momentum Stock to Buy
Does Repligen (RGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Insider Monkey
Hedge Funds Hit The Bullseye With This Stock Pick
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms' equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
- Zacks
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
Is (RGEN) Outperforming Other Medical Stocks This Year?
- Thomson Reuters StreetEvents
Edited Transcript of RGEN earnings conference call or presentation 31-Oct-19 12:30pm GMT
Q3 2019 Repligen Corp Earnings Call
- Zacks
Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance
Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.
- Zacks
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
Repligen (RGEN) delivered earnings and revenue surprises of 30.00% and 5.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Repligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-yearRaises revenue guidance to $267-$270 million for full year.
- Simply Wall St.
Does Repligen Corporation's (NASDAQ:RGEN) CEO Pay Matter?
Tony Hunt has been the CEO of Repligen Corporation (NASDAQ:RGEN) since 2015. This analysis aims first to contrast CEO...
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Repligen Corporation (RGEN)
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Zacks
Repligen (RGEN) Reports Next Week: What to Expect
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Repligen to Report Third Quarter 2019 Financial Results
Repligen Corporation (RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2019. The conference call will be accessible by dialing toll-free (844) 701-1063 for domestic callers and (412) 317-5487 for international callers.
- Thomson Reuters StreetEvents
Edited Transcript of RGEN earnings conference call or presentation 1-Aug-19 12:30pm GMT
Q2 2019 Repligen Corp Earnings Call
- Simply Wall St.
Does The Repligen Corporation (NASDAQ:RGEN) Share Price Fall With The Market?
Anyone researching Repligen Corporation (NASDAQ:RGEN) might want to consider the historical volatility of the share...
- CNW Group
Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes
TORONTO and HOUSTON , Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced the appointment of Ms. Karen Dawes to the Board of Directors of Medicenna and the voting results from the Company's annual meeting of shareholders held today, September 24, 2019 in Toronto (the "Meeting"). A total of 36.15% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.
- Zacks
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
Sector ETF report for PSCH
- InvestorPlace
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
On the stump, if there's one thing that both Republican and Democratic politicians have long claimed to support, it's lower drug prices. And when rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed…some fairly, and some not (as we'll see).That's just what happened in the past week.House Speaker Nancy Pelosi has a tougher proposal on her agenda than, say, President Trump. While the Trump administration is more interested in importing lower-priced versions of the drugs from Canada, Pelosi wants to apply direct pressure to pharmaceutical companies.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSpecifically, Pelosi wants to allow the Dept. of Health & Human Services to negotiate prices for Medicare Part D drug plans directly with drug manufacturers. (That would, effectively, eject pharmacy benefit managers and insurance companies from the negotiating table.)Several biotech stocks have taken big hits on the regulatory rumors. Some of the Big Pharma crowd even showed up on the list of three-year lows last week! Let's review - because while some deserve to be sold, one big mover is actually on my Top 5 Stocks list for Breakthrough Stocks. * 7 Discount Retail Stocks to Buy for a Recession First we have Biogen (NASDAQ:BIIB), a potential target of Pelosi's proposal. With its famously pricey drug for spinal muscular atrophy, Spiranza, Biogen may well come into Democrats' crosshairs here. BIIB stock dropped sharply last Friday and again on Thursday.You may think that with pricing like $750,000 for your first year of Spiranza, Biogen would be printing money. But Spiranza just picked up a competitor from Novartis (NYSE:NVS). And below is the full picture on BIIB stock from my Portfolio Grader:While Biogen passes some of my profitability tests, it gets an F for Earnings Momentum, and Sales Growth is lackluster as well. Most concerning is the fact that BIIB stock got a D for its Quantitative Grade - my proprietary measure of institutional buying pressure.Regeneron Pharmaceuticals (NASDAQ:REGN) is looking even worse. The stock got off to a rough start this week, and while it's clawed back somewhat, it's still down 8% in the past month. For its part, Regeneron has a cholesterol drug (Praluent) that was so expensive that it eventually succumbed to pressure, reduced prices by 60%, and yet it still costs $5,850 a year.Here's REGN's Report Card:As you see above, Regeneron just does not measure up on Operating Margin Growth, Earnings Growth, Earnings Momentum or its Quantitative Grade.Then there's Repligen (NASDAQ:RGEN). While it may have a similar name and ticker, RGEN has much stronger fundamentals. Shares took an even bigger hit - but this is a much more interesting case.Repligen is a unique biotech: This company actually has no drugs of its own, but rather, its products are used in drug manufacturing.Repligen hit the biotechnology scene back in 1981, as it started to develop Protein A ligands to aid in the production of biologic treatments. The company has expanded rapidly since then, and was even named one of the Top 100 fastest-growing companies in the U.S. in 2018. Today, along with Protein A ligands, Repligen offers several products and solutions to enhance the production of biologic drugs.Strong demand for Repligen's biologic solutions was apparent in the company's second-quarter earnings report. The company reported 48% annual revenue growth and 121.4% annual earnings growth. Plus, second-quarter earnings of $0.31 per share crushed estimates for $0.25 per share by 24%.Given the strong second-quarter results, analysts have increased full-year 2019 forecasts in the past two months. Analysts are forecasting 32.9% annual earnings growth and 37.1% annual sales growth.This all makes for a very impressive Report Card on RGEN, as you see here:So, when this kind of stock drops as hard as RGEN just did, I view it as a chance to pick up shares at "bargain basement" prices for a great, long-term play. There's Something Else That Sets These Breakthrough Stocks ApartIf you take a look at RGEN stock, you'll notice its much smaller market cap of $4 billion, versus giant biotech stocks like BIIB and REGN with $30 billion (or more)!If you're a growth investor - and I certainly am; I've made my career this way - then you've got to look at elite small-caps like this. With growth statistics like RGEN's (and my other Breakthrough Stocks), the sky is the limit.RGEN is 4 on my list of Top 5 Stocks. To get my buy price - and the rest of the list - check out Breakthrough Stocks now. When you do, you'll learn all about my "Quantum A" system for identifying the best small-cap investments.Ultimately, spotting the right investment is simple. You buy when the company achieves a Quantum A …and you sell when it disappears.You don't fall in love. You certainly don't fall for hype. You may return to that stock someday - but with my system, you know exactly when it's time to take profits off the table.That's why I always say: There's no luck and very little skill behind my own success - just hard work. And the result: a proprietary system for picking the best investments of the day. It's made it easy to nab market-beating returns - for double your money (or better).I'm eager to show you what my system is picking up now. Click here to find out more.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector appeared first on InvestorPlace.
